Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
← Research & Industry News
External source

Orphan Therapeutics Accelerator In-Licenses Its First Gene Therapy, Eyes Pipeline Expansion

The nonprofit biotech evaluates potential therapies based on unmet medical need, clinical evidence of safety and efficacy, and the compatibility of institutional partners. Its funding model combines initial seed investment with commercial revenue and non-traditional funding sources.

Published by
GEN — Genetic Engineering & Biotechnology News
Evidence type
Industry

The nonprofit biotech evaluates potential therapies based on unmet medical need, clinical evidence of safety and efficacy, and the compatibility of institutional partners. Its funding model combines initial seed investment with commercial revenue and non-traditional funding sources.

This item was selected automatically by our daily literature and news monitor because it matches the topics we follow. Read the full story at GEN — Genetic Engineering & Biotechnology News.

Gene Delivery & Transfection

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.
Orphan Therapeutics Accelerator In-Licenses Its First Gene Therapy, Eyes Pipeline Expansion | Brilliant Blue Biosciences